Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous BMMNCs Combined With Bio-oss for Severe Maxillofacial Bone Defects
NCT07852806Recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Nov 2022
- Primary completion
- Jan 2027
- Countries
- 1
01
Overview
Open-label, single-arm trial of autologous bone marrow-derived mononuclear cell in maxillofacial bone defect and Alveolar bone loss, sponsored by Nanjing Drum-Tower Hospital. Primary endpoint: New bone volume fraction in the grafted bone defect area at 6 months. Started Nov 2022; status: recruiting.
02
Drugs
autologous bone marrow-derived mononuclear cell
03
Conditions
maxillofacial bone defectAlveolar bone loss
Beyond the preview
Go deeper on NCT07852806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07852806.